Bob has a deep history in large and emerging stage pharma, building bioscience companies and creating significant value for investors. His last two strategic exits created 11x and 18x returns for the company’s investors. He has worked in and outside the United States and has long-standing experience in drug delivery having led the development and commercialization of several seminal inventions in the field. Bob has attracted senior level research and business leadership from top tier pharmaceutical companies. He serves as the Company’s Executive Chair. Bob founded Continuity Biosciences, LLC, in 2024 and serves as its Executive Chairman. He completed the acquisition of a series of drug delivery technologies from The Methodist Hospital in Houston, Texas, and has recruited a top tier list of scientific operating executives and advisors to shepherd the Company through its initial phase. Bob is a co-founder of Sprout Pharmaceuticals, a biopharmaceutical company, and currently serves as Chairman of its Board of directors. Previously, Bob co-founded and served as Chief Executive Officer and a director of Slate until Slate’s acquisition in December 2011. Bob is recognized for purchasing undervalued pharmaceutical assets and liquidating them through strategic transactions for hundreds of millions to more than a billion dollars. Bob is a seed stage investor and participates as an investor and advisor to multiple start-up healthcare firms, including Lia, IntuiTap, uMethod and several others. He has recently been the CEO of Isleworth Healthcare Acquisition Corporation and is a Sponsor of Global Blockchain Acquisition Corp as well as ESH Acquisition Corporation.